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Abstract
A 26-year-old male experienced a recurrence of idiopathic
focal segmental glomerulosclerosis (iFSGS) after his sec-
ond renal transplant. Reduction of proteinuria was rapidly
induced by plasmapheresis (PP) and the patient has re-
mained in remission with a once-weekly PP regimen,
which has now been continued for >3½ years. We were
also able to induce remission of iFSGS in this patient by
treatment with high cut-off haemodialysis using the Ther-
alite  dialyser. This observation lends support for the path-
ophysiological role of an as yet unknown, circulating
glomerular ﬁltration barrier permeability factor with an es-
timated weight of between 30 and 50 kDa.
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Background
Idiopathic focal segmental glomerulosclerosis (iFSGS) re-
curs after renal transplantation in ~20% of cases and the
chance of recurrence after a second renal transplant exceeds
80% [1,2]. The pathogenesis of iFSGS is unknown but
there is evidence that the disease is caused by an incom-
pletely characterized circulating glomerular ﬁltration bar-
rier permeability factor [3,4]. Plasmapheresis (PP) is
effective in treating recurrent iFSGS after transplantation,
possibly by removing this unknown permeability factor
[3,5]. Therefore, early treatment of recurrent iFSGS with
PP is recommended but detailed descriptions of treatment
regimens are lacking [6–8]. Recently, high cut-off (HCO)
dialysers have become available which allow for the re-
moval of molecules with a molecular weight of up to 45
kDa. HCO-dialysers have been used successfully to re-
move light chain immunoglobulins in patients with mye-
loma cast nephropathy [9,10].
Wedescribe a patient who achieveda sustained remission
of recurrent iFSGS after receiving a second renal transplant
with long-term maintenance PP and HCO-haemodialysis.
Case history
A 26-year-old male patient received a second, three human
leucocyte antigen (HLA) mismatched (A, B and DR) kid-
ney transplant from a living-related donor in January 2007.
Immunosuppression consisted of tacrolimus, mycophenolate
mofetil and prednisolone without induction therapy. He
had been diagnosed with steroid-resistant iFSGS of the
native kidneys when he was 19 years old. Renal failure
developed within 3 years and haemodialysis was initiated.
His ﬁrst living-related HLA-identical kidney transplanta-
tion in 2004 was complicated by a rapid recurrence of
iFSGS. Symptomatic therapy with angiotensin-converting
enzyme (ACE)-inhibitors was started and 1½ years after
transplantation, his graft failed, necessitating haemodialy-
sis. Prior to his second transplantation, a transplant neph-
rectomy was performed. Hereafter, the patient became
anuric and therefore the native kidneys were left in situ.
The donor of the second transplant (his mother) had a
normal renal function without hypoalbuminaemia or pro-
teinuria at the time of donation and remains in good clinical
condition with a normal renal function some 3 years after
donation. His second renal transplantation was complicated
by a biopsy-proven vascular and tubulointerstitial rejection
on Day 3 (acute rejection Type IIA, t1v1g0i0 according to
the Banff criteria), which was treated successfully with
high-dose steroids and rabbit anti-thymocyte globulin
(rATG). When renal function improved, proteinuria devel-
oped. Electron microscopic examination of the transplant
biopsy taken on Day 3 after transplantation showed podo-
cyte foot effacement. Recurrent iFSGS was diagnosed.
Daily PP treatment was initiated at a dose of 2.4 L plasma
volume exchange with fresh frozen plasma as substitution
ﬂuid (Figure 1). In addition, the patient was treated with
ACE-inhibition (fosinopril 20 mg twice daily) and an an-
giotensin receptor blocker (losartan 50 mg twice daily).
Remission of proteinuria was swift but returned within 2
weeks after cessation of PP. After another two cycles of PP,
urinary protein excretion was again signiﬁcantly reduced.
Because anecdotal reports have suggested that anti-CD20
immunotherapy may be effective in treating post-transplant
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375 mg/m
2 [11]. Thereafter, circulating B cells were com-
pletely depleted but to no apparent effect on proteinuria.
We decided to continue PP after inducing remission of the
proteinuria by daily PP, in once-weekly sessions exchang-
ing plasma volume with 4 L of a 4% albumin solution. This
regimen kept the proteinuria at 0.5 g/24 h. Reducing the
frequency of PP to once every 2 weeks (at Day 182 post-
transplantation) led to an increase of proteinuria necessitat-
ing a short interval of intensiﬁed PP treatment. The PP
sessions were all tolerated well.
Some2½yearsaftertransplantation,asecondrenalbiopsy
was performed because of a slowly deteriorating renal func-
tion and slight increase in proteinuria. The histological ﬁnd-
ingswereconsistent with recurrentFSGS, cellular variant. In
addition, moderate calcineurin inhibitor nephrotoxicity was
present (arteriolar hyalinosis and isometric tubular vacuoli-
zation). The tacrolimus dose was reduced aiming for predose
concentrations of 5–6 ng/mL rather than 8 ng/mL.
In March 2010, after ~200 PP sessions, we started treat-
ing the patient with HCO-haemodialysis by use of the
Theralite  HCO dialyser (Gambro , Zaventem, Belgium)
in an attempt to reduce the intensity of his treatment. At
this time, his medication consisted of tacrolimus, predni-
solone and fosinopril. Treatment with mycophenolate
mofetil had been stopped 2 years previously because of
pancytopenia. HCO-haemodialysis was started 2 weeks
after the last PP during which time his proteinuria
increased from 0.5 g to >2 g/day (Figure 2). Initially,
HCO-haemodialysis was performed every other day for
4 h, which led to a rapid reduction of proteinuria. However,
reduction of the HCO-haemodialysis frequency to once a
week led to an increase of proteinuria. More intensive
HCO-haemodialysis was initiated, again followed by a
rapid and very good partial response, which was compa-
rable to that seen during treatment with PP. A second
attempt to reduce the treatment interval to once a week, once
more led to an increase of urinary protein excretion. Here-
after, because of the intensity of the HCO-haemodialysis
regimen,werestartedonce-weeklyPP.Eversince,thepatient
has remained in remission with once-weekly PP and is in an
excellent clinical condition. During HCO-haemodialysis
plasma–albumin levels decreased slightly below the normal
range (with a nadir of 31 g/L) but otherwise no serious ad-
verse effects, such as allergic reactions or infections, were
noted.
Discussion
The patient reported herein remained in sustained remis-
sion with once-weekly PP for a period of >3½ years after
recurrence of iFSGS following a second renal transplant.
Our ﬁndings support the pathophysiological role of an
unknown circulating permeability factor [3,4]. Firstly,
the patient remained in remission independently of the
substitution ﬂuid used, suggesting that the removal rather
than the substitution of an unknown circulating factor is of
importance. Secondly, the amount of proteinuria (and its
recurrence) in response to PP fully matches a ﬁrst-order
kinetics of elimination and implies a direct and rapidly
reversible effect of a circulating factor on glomerular ﬁl-
tration barrier permeability. Thirdly, HCO-haemodialysis
was successfully used to induce remission after PP was
temporarily discontinued. The HCO Theralite  ﬁlter al-
lows removal of molecules with a molecular weight of 45
kDa, whereas the as yet unknown circulating permeability
factor in iFSGS presumably has a molecular weight of 30–
50 kDa [3,4,7]. Our observations are therefore in line with
the presumed pathophysiological role of the circulating
permeability factor. Recently, by use of proteomic techni-
ques, McCarthy et al. [12] proposed cardiotrophin-like
cytokine-1 and soluble urokinase receptor as active factors
in iFSGS.
Due to ethical considerations, we did not attempt to dial-
yse our patient with a standard low cut-off ﬁlter. If dialysis
using a low cut-off ﬁlter would have been unsuccessful in
inducing remission, this would have provided additional
evidence for the proposed molecular weight of the per-
meability factor of 30–50 kDa rather than a smaller mole-
cule. In addition, although HCO-haemodialysis was used
Fig. 1. Evolution of serum creatinine (ﬁlled circles) and proteinuria (open
circles) after transplantation. The ﬁlled triangles represent single PP treat-
ments. The two open triangles represent the two doses of rituximab (375
mg/m
2 each).
Fig. 2. Effect of HCO-haemodialysis with the Theralite  dialyser on
proteinuria. The urine protein to creatinine ratio is depicted by the open
circles. The ﬁlledcircles represent the serumcreatinine.The ﬁlledtriangles
represent single PP treatments, whereas the open triangles represent dial-
ysis treatments with the HCO dialyser.
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the level ofproteinuria <1 g/L.Becauseofthe relatively low
effectiveness of our HCO-haemodialysis regimen as com-
pared with once-weekly PP, the size of the unknown per-
meability factor is likely to be near the 45 kDa cut-off of the
Theralite  dialyser. Possibly, we might have achieved a
higher clearance if we had dialysed our patient for 6–8 h
rather than 4 h, as was described by Hutchinson et al. [9,10]
for the treatment of light chain disease. The reason we did
not was that our patient refused to be treated with longer
dialysis sessions. Finally, the costs of the HCO-haemodial-
ysis regimen we used were about four times higher than
that of regular once-weekly PP. Therefore, our observa-
tions show that HCO-haemodialysis is effective in inducing
remission of recurrent iFSGS after transplantation (the
proof of principle) but that it is not a realistic alternative
to once-weekly PP.
In conclusion, we report the long-term efﬁcacy of once-
weekly PP for recurrent iFSGS after renal transplantation.
Evidence for the pathophysiological role of an unknown
30–50 kDa permeability factor was strengthened by the
demonstration of the effectiveness of HCO-haemodialysis
to induce remission. The value of this protocol needs to be
established in a larger group of patients with recurrent
iFSGS after renal transplantation.
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